

Cover Story
Free
By Matthew Bin Han Ong
The Blue Ribbon Panel—a group of experts selected to identify scientific opportunities for the National Cancer Moonshot Initiative—has submitted 10 recommendations to the National Cancer Advisory Board.
By Laura Brawley
In Brief


Drugs & Targets


Trending Stories
- Caught in the crossfire: The critical threats facing cancer centers, research, and patient care
- Columbia’s cancer center becomes collateral damage in Trump’s war on antisemitism
- FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers
- Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills - Trump’s tariffs will likely affect cancer drugs and devices—and may deepen drug shortages
- The University of Rochester Wilmot Cancer Institute earns NCI Cancer Center designation